|
1
|
Burnstock G: Purinergic signalling:
Pathophysiology and therapeutic potential. Keio J Med. 62:63–73.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braganhol E, Wink MR, Lenz G and
Battastini AM: Purinergic signaling in glioma progression. Adv Exp
Med Biol. 986:81–102. 2013. View Article : Google Scholar
|
|
3
|
Burnstock G: Introduction: P2 receptors.
Curr Top Med Chem. 4:793–803. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Solini A, Cuccato S, Ferrari D, Santini E,
Gulinelli S, Callegari MG, Dardano A, Faviana P, Madec S, Di
Virgilio F, et al: Increased P2X7 receptor expression and function
in thyroid papillary cancer: A new potential marker of the disease?
Endocrinology. 149:389–396. 2008. View Article : Google Scholar
|
|
5
|
Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G,
Rao Q, Nie K and Wu KF: Expression of P2X7 in human hematopoietic
cell lines and leukemia patients. Leuk Res. 28:1313–1322. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Qi X, Zhou L, Catera D, Rote NS,
Potashkin J, Abdul-Karim FW and Gorodeski GI: Decreased expression
of P2X7 in endometrial epithelial pre-cancerous and cancer cells.
Gynecol Oncol. 106:233–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Zhou L, Feng YH, Abdul-Karim FW and
Gorodeski GI: The P2X7 receptor: A novel biomarker of uterine
epithelial cancers. Cancer Epidemiol Biomarkers Prev. 15:1906–1913.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
9
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jelassi B, Chantôme A, Alcaraz-Pérez F,
Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A and Roger S:
P2X(7) receptor activation enhances SK3 channels- and cystein
cathepsin-dependent cancer cells invasiveness. Oncogene.
30:2108–2122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun SH: Roles of P2X7 receptor in glial
and neuroblastoma cells: The therapeutic potential of P2X7 receptor
antagonists. Mol Neurobiol. 41:351–355. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng S, Qiao M and Pardee AB: Metastasis
and AKT activation. J Cell Physiol. 218:451–454. 2009. View Article : Google Scholar
|
|
14
|
Yang G, Zhang S, Zhang Y, Zhou Q, Peng S,
Zhang T, Yang C, Zhu Z and Zhang F: The inhibitory effects of
extracellular ATP on the growth of nasopharyngeal carcinoma cells
via P2Y2 receptor and osteopontin. J Exp Clin Cancer Res.
33:532014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li WH, Qiu Y, Zhang HQ, Liu Y, You JF,
Tian XX and Fang WG: P2Y2 receptor promotes cell invasion and
metastasis in prostate cancer cells. Br J Cancer. 109:1666–1675.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi K, Queiroz KC, Stap J, Richel DJ and
Spek CA: Protease-activated receptor-2 induces migration of
pancreatic cancer cells in an extracellular ATP-dependent manner. J
Thromb Haemost. 11:1892–1902. 2013.PubMed/NCBI
|
|
17
|
Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang
XX, Liu JM, Ning G and Zhao YJ: Association of XIAP and P2X7
receptor expression with lymph node metastasis in papillary thyroid
carcinoma. Endocrine. 38:276–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kwon JH, Nam ES, Shin HS, Cho SJ, Park HR
and Kwon MJ: P2X7 receptor expression in coexistence of papillary
thyroid carcinoma with Hashimoto’s thyroiditis. Korean J Pathol.
48:30–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adinolfi E, Raffaghello L, Giuliani AL,
Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V
and Di Virgilio F: Expression of P2X7 receptor increases in vivo
tumor growth. Cancer Res. 72:2957–2969. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hattori F, Ohshima Y, Seki S, Tsukimoto M,
Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, Harada H, et al:
Feasibility study of B16 melanoma therapy using oxidized ATP to
target purinergic receptor P2X7. Eur J Pharmacol. 695:20–26. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takai E, Tsukimoto M, Harada H and Kojima
S: Autocrine signaling via release of ATP and activation of P2X7
receptor influences motile activity of human lung cancer cells.
Purinergic Signal. 10:487–497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y and Zhou BP: Epithelial-mesenchymal
transition in breast cancer progression and metastasis. Chin J
Cancer. 30:603–611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davis FM, Kenny PA, Soo ET, van Denderen
BJ, Thompson EW, Cabot PJ, Parat MO, Roberts-Thomson SJ and
Monteith GR: Remodeling of purinergic receptor-mediated
Ca2+ signaling as a consequence of EGF-induced
epithelial-mesenchymal transition in breast cancer cells. PLoS One.
6:e234642011. View Article : Google Scholar
|
|
24
|
Paredes J, Figueiredo J, Albergaria A,
Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM,
Simões-Correia J, Oliveira MJ, et al: Epithelial E- and
P-cadherins: Role and clinical significance in cancer. Biochim
Biophys Acta. 1826:297–311. 2012.PubMed/NCBI
|
|
25
|
Morrison C, Mancini S, Cipollone J,
Kappelhoff R, Roskelley C and Overall C: Microarray and proteomic
analysis of breast cancer cell and osteoblast co-cultures: Role of
osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J
Biol Chem. 286:34271–34285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pivetta E, Scapolan M, Pecolo M,
Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C,
Colombatti A and Spessotto P: MMP-13 stimulates osteoclast
differentiation and activation in tumour breast bone metastases.
Breast Cancer Res. 13:R1052011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Gong LH, Zhang HQ, Du Q, You JF,
Tian XX and Fang WG: Extracellular ATP enhances in vitro invasion
of prostate cancer cells by activating Rho GTPase and upregulating
MMPs expression. Cancer Lett. 293:189–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vázquez-Cuevas FG, Martínez-Ramírez AS,
Robles-Martínez L, Garay E, García-Carrancá A, Pérez-Montiel D,
Castañeda-García C and Arellano RO: Paracrine stimulation of P2X7
receptor by ATP activates a proliferative pathway in ovarian
carcinoma cells. J Cell Biochem. 115:1955–1966. 2014.PubMed/NCBI
|
|
29
|
Bian S, Sun X, Bai A, Zhang C, Li L,
Enjyoji K, Junger WG, Robson SC and Wu Y: P2X7 integrates PI3K/AKT
and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell
death. PLoS One. 8:e601842013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lauring J, Park BH and Wolff AC: The
phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target
in breast cancer. J Natl Compr Canc Netw. 11:670–678.
2013.PubMed/NCBI
|
